Ignite Creation Date:
2025-12-26 @ 10:32 AM
Ignite Modification Date:
2025-12-31 @ 4:06 PM
Study NCT ID:
NCT05390528
Status:
UNKNOWN
Last Update Posted:
2023-08-08
First Post:
2022-04-25
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study Evaluating the Safety, Tolerability, Pharmacokinetic and Efficacy of HLX301(TIGIT×PDL1 Bispecific) in Locally Advanced/Metastatic Solid Tumors or Lymphoma
Sponsor:
Shanghai Henlius Biotech
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-06-20
Start Date Type:
ACTUAL
Primary Completion Date:
2023-09-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2024-12-30
Completion Date Type:
ESTIMATED
First Submit Date:
2022-04-25
First Submit QC Date:
None
Study First Post Date:
2022-05-25
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-08-07
Last Update Post Date:
2023-08-08
Last Update Post Date Type:
ACTUAL